Key Drivers
- Strong Margins
- Dividend Coverage
- Thin Liquidity
AIAI Summary
JNJ is no longer just a defensive dividend stock; it is a self-funding healthcare compounder whose upside now hinges on converting pipeline wins and MedTech recovery into durable EPS growth while finally reducing talc/legal overhang, since the current valuation already reflects its stability.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Margins
- •Dividend Coverage
- •Thin Liquidity
JNJ remains financially resilient with strong margins, robust cash flow, and comfortable dividend coverage, but moderate leverage, thin liquidity, and a premium valuation limit upside.
Price Behavior
Key Price Behavior Insights:
- •Support forming
- •Resistance capped
- •Rebound stalled
JNJ has improved over the last month with support forming around $255-$256, but repeated failures near $265-$267 leave the trend neutral to mildly positive until a breakout occurs.
Brief dip to $254.41-$254.93 was quickly reversed back above $260
Sentiment & News
Key News Insights:
- •Q2 Beat
- •Analyst Support
- •Institutional Activity
Johnson & Johnson posted a strong Q2 beat and raised guidance, with supportive analyst sentiment and steady institutional activity offsetting lingering MedTech and legal concerns.
The news trend is mildly positive for JNJ, signaling resilient fundamentals and continued investor interest despite some operational headwinds
Similar Companies in Healthcare
Other companies in the same sector with AI ratings